DHTKD1: A Potential Drug Target and Biomarker for Mitochondrial Enrichment

Target Name: DHTKD1

NCBI ID: G55526

DHTKD1: A Potential Drug Target and Biomarker for Mitochondrial Enrichment

Dietary changes and physical activity are associated with a range of health benefits, including improved cardiovascular health, enhanced muscle strength, and increased lifespan. However, the underlying mechanisms by which these benefits are achieved are not fully understood. One potential explanation for these benefits is the role of mitochondria, which are energy-producing structures found in all eukaryotic cells. Activated mitochondria produce reactive oxygen species (ROS) that can generate reactive oxygen species (ROS) during periods of muscle contraction and fatigue, leading to cellular damage and dysfunction.

Gut microbiota have been shown to play a crucial role in modulating the gut-brain axis and influencing host inflammatory responses. The gut-brain axis is a bidirectional communication network that links the gut microbiota to the central nervous system, and it has been implicated in various neurological disorders, including anxiety, depression, and neurodegenerative diseases.

The mitochondrial Enrichment (MIToEnrich) assay is a widely used method to study the effects of drugs on mitochondrial function, and it has been applied to the study of various diseases, including neurodegenerative diseases. The DHTKD1 gene has been shown to be involved in the mitochondrial Enrich assay, and it has potential as a drug target or biomarker.

DHTKD1: The Mitochondrial Enrich Assay

The DHTKD1 gene encodes the protein Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, which is a key enzyme in the mitochondrial Enrich assay. The Enrich assay is a technique that has been used to study the effects of drugs on various cellular processes, including mitochondrial function.

In the DHTKD1 gene, the first exon encodes a 23 amino acid protein, which is the DHKTD1 enzyme. The second exon encodes a 21 amino acid protein, which is a non-coding RNA molecule. The non-coding RNA molecule is processed by the splicing machinery into a functional protein that is involved in the mitochondrial Enrich assay.

The mitochondrial Enrich assay is a cell-based assay that has been used to study the effects of drugs on various cellular processes, including mitochondrial function. In this assay, cells are treated with a drug and then isolated at various time points to measure changes in cellular processes, including mitochondrial function.

DHTKD1: Potential Drug Target

The DHTKD1 gene has been shown to be involved in the mitochondrial Enrich assay, and it has potential as a drug target. The DHKTD1 enzyme is involved in the citric acid cycle, which is a central metabolic pathway that is critical for energy production.

In neurodegenerative diseases, the disruption of normal cellular metabolism is thought to contribute to the development and progression of these conditions. The DHKTD1 enzyme has been shown to be involved in the regulation of cellular metabolism, and it has potential as a drug target.

DHTKD1: Potential Biomarker

The DHTKD1 gene has also been shown to be involved in the regulation of cellular processes that are relevant to various neurological disorders. The DHTKD1 enzyme has been shown to be involved in the regulation of mitochondrial function, which is critical for the production of energy in the brain.

In Alzheimer's disease, which is a neurodegenerative disorder that is characterized by the progressive loss of brain cells, the disruption of normal cellular metabolism is thought to contribute to the development and progression of this condition. The DHKTD1 enzyme has

Protein Name: Dehydrogenase E1 And Transketolase Domain Containing 1

Functions: 2-oxoadipate dehydrogenase (E1a) component of the 2-oxoadipate dehydrogenase complex (OADHC) (PubMed:29191460, PubMed:29752936, PubMed:32303640, PubMed:32633484, PubMed:32695416). Participates in the first step, rate limiting for the overall conversion of 2-oxoadipate (alpha-ketoadipate) to glutaryl-CoA and CO(2) catalyzed by the whole OADHC (PubMed:29191460, PubMed:32695416). Catalyzes the irreversible decarboxylation of 2-oxoadipate via the thiamine diphosphate (ThDP) cofactor and subsequent transfer of the decarboxylated acyl intermediate on an oxidized dihydrolipoyl group that is covalently amidated to the E2 enzyme (dihydrolipoyllysine-residue succinyltransferase or DLST) (Probable) (PubMed:29752936, PubMed:32303640, PubMed:32633484). Can catalyze the decarboxylation of 2-oxoglutarate in vitro, but at a much lower rate than 2-oxoadipate (PubMed:29191460, PubMed:29752936, PubMed:32633484, PubMed:32695416). Responsible for the last step of L-lysine, L-hydroxylysine and L-tryptophan catabolism with the common product being 2-oxoadipate (Probable)

More Common Targets